Edesa Biotech Stock Performance
| EDSA Stock | USD 2.17 0.06 2.84% |
The firm shows a Beta (market volatility) of 1.48, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Edesa Biotech will likely underperform. At this point, Edesa Biotech has a negative expected return of -1.11%. Please make sure to confirm Edesa Biotech's skewness, day typical price, and the relationship between the maximum drawdown and daily balance of power , to decide if Edesa Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Edesa Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 3.33 | Five Day Return 3.33 | Year To Date Return (53.63) | Ten Year Return (99.95) | All Time Return (99.63) |
Last Split Factor 1:7 | Dividend Date 2019-06-10 | Last Split Date 2023-10-11 |
1 | Acquisition by Nijhawan Pardeep of 3055 shares of Edesa Biotech subject to Rule 16b-3 | 09/03/2024 |
2 | Acquisition by Pardeep Nijhawan Medicine Professional Corp of 5000 shares of Edesa Biotech at 1.9198 subject to Rule 16b-3 | 09/12/2024 |
3 | Insider Trading | 09/13/2024 |
4 | Acquisition by Nijhawan Pardeep of 3300 shares of Edesa Biotech subject to Rule 16b-3 | 10/02/2024 |
5 | Acquisition by Nijhawan Pardeep of 150 shares of Edesa Biotech at 3.445 subject to Rule 16b-3 | 10/30/2024 |
6 | Acquisition by Niffenegger Kathi of 80000 shares of Edesa Biotech at 5.45 subject to Rule 16b-3 | 11/01/2024 |
7 | Acquisition by Brooks Michael J of 3000 shares of Edesa Biotech at 1.4943 subject to Rule 16b-3 | 11/06/2024 |
8 | Acquisition by Nijhawan Pardeep of 4630 shares of Edesa Biotech subject to Rule 16b-3 | 11/12/2024 |
9 | EDSA stock touches 52-week low at 2.08 amid market challenges By Investing.com - Investing.com South Africa | 11/20/2024 |
| Begin Period Cash Flow | 7.1 M |
Edesa |
Edesa Biotech Relative Risk vs. Return Landscape
If you would invest 470.00 in Edesa Biotech on August 27, 2024 and sell it today you would lose (253.00) from holding Edesa Biotech or give up 53.83% of portfolio value over 90 days. Edesa Biotech is currently does not generate positive expected returns and assumes 4.1545% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Edesa, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Edesa Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Edesa Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Edesa Biotech, and traders can use it to determine the average amount a Edesa Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2672
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EDSA |
Estimated Market Risk
| 4.15 actual daily | 36 64% of assets are more volatile |
Expected Return
| -1.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.27 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Edesa Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Edesa Biotech by adding Edesa Biotech to a well-diversified portfolio.
Edesa Biotech Fundamentals Growth
Edesa Stock prices reflect investors' perceptions of the future prospects and financial health of Edesa Biotech, and Edesa Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Edesa Stock performance.
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | 5.04 M | ||||
| Shares Outstanding | 3.25 M | ||||
| Price To Earning | (3.96) X | ||||
| Price To Book | 2.46 X | ||||
| Price To Sales | 120,478 X | ||||
| Gross Profit | 311.2 K | ||||
| EBITDA | (9.22 M) | ||||
| Net Income | (8.37 M) | ||||
| Cash And Equivalents | 12.81 M | ||||
| Cash Per Share | 0.83 X | ||||
| Total Debt | 94.49 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 0.88 X | ||||
| Cash Flow From Operations | (6.64 M) | ||||
| Earnings Per Share | (19.78) X | ||||
| Market Capitalization | 7.05 M | ||||
| Total Asset | 8.89 M | ||||
| Retained Earnings | (52.42 M) | ||||
| Working Capital | 4.61 M | ||||
| Current Asset | 6.92 M | ||||
| Current Liabilities | 581.49 K | ||||
About Edesa Biotech Performance
By analyzing Edesa Biotech's fundamental ratios, stakeholders can gain valuable insights into Edesa Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Edesa Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Edesa Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 45.16 | 47.42 | |
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (1.10) | (1.15) |
Things to note about Edesa Biotech performance evaluation
Checking the ongoing alerts about Edesa Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Edesa Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Edesa Biotech generated a negative expected return over the last 90 days | |
| Edesa Biotech has high historical volatility and very poor performance | |
| Net Loss for the year was (8.37 M) with profit before overhead, payroll, taxes, and interest of 311.2 K. | |
| Edesa Biotech currently holds about 12.81 M in cash with (6.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
| Edesa Biotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 33.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: EDSA stock touches 52-week low at 2.08 amid market challenges By Investing.com - Investing.com South Africa |
- Analyzing Edesa Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Edesa Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Edesa Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Edesa Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Edesa Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Edesa Biotech's stock. These opinions can provide insight into Edesa Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Edesa Stock analysis
When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |